Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

A. C. Rawstron, S. Böttcher, R. Letestu, N. Villamor, C. Fazi, H. Kartsios, R. M. De Tute, J. Shingles, M. Ritgen, C. Moreno, K. Lin, A. R. Pettitt, M. Kneba, E. Montserrat, F. Cymbalista, M. Hallek, P. Hillmen, P. Ghia

Research output: Contribution to journalArticle

Abstract

Detection of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) is becoming increasingly important as treatments improve. An internationally harmonised four-colour (CLR) flow cytometry MRD assay is widely used but has limitations. The aim of this study was to improve MRD analysis by identifying situations where a less time-consuming CD19/CD5/κ/λ analysis would be sufficient for detecting residual CLL, and develop a six-CLR antibody panel that is more efficient for cases requiring full MRD analysis. In 784 samples from CLL patients after treatment, it was possible to determine CD19/CD5/κ/λ thresholds that identified cases with detectable MRD with 100% positive predictive value (PPV). However, CD19/CD5/κ/λ analysis was unsuitable for predicting iwCLL/NCI response status or identifying cases with no detectable MRD. For the latter cases requiring a full MRD assessment, a six-CLR assay was designed comprising CD19/CD5/CD20 with (1) CD3/CD38/CD79b and (2) CD81/CD22/CD43. There was good correlation between four-CLR and six-CLR panels in dilution studies and clinical samples, with 100% concordance for detection of residual disease at the 0.01% (10-4) level (n=59) and good linearity even at the 0.001-0.01% (10-5-10-4) level. A six-CLR panel therefore provides equivalent results to the four-CLR panel but it requires fewer reagents, fewer cells and a much simpler analysis approach.

Original languageEnglish
Pages (from-to)142-149
Number of pages8
JournalLeukemia
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • chronic lymphocytic leukaemia
  • flow cytometry
  • minimal residual disease

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL'. Together they form a unique fingerprint.

  • Cite this

    Rawstron, A. C., Böttcher, S., Letestu, R., Villamor, N., Fazi, C., Kartsios, H., De Tute, R. M., Shingles, J., Ritgen, M., Moreno, C., Lin, K., Pettitt, A. R., Kneba, M., Montserrat, E., Cymbalista, F., Hallek, M., Hillmen, P., & Ghia, P. (2013). Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia, 27(1), 142-149. https://doi.org/10.1038/leu.2012.216